diallyl-(2-chloro-ethyl)-amine | 81637-44-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: diallyl-(2-chloro-ethyl)-amine
• 英文别名: 1-Chlor-2-diallylamino-aethan；Diallyl-(2-chlor-aethyl)-amin；n-(2-Chloroethyl)-n-(prop-2-en-1-yl)prop-2-en-1-amine；N-(2-chloroethyl)-N-prop-2-enylprop-2-en-1-amine
• CAS: 81637-44-7
• 化学式: C₈H₁₄ClN
• mdl: MFCD15207266
• 分子量: 159.659
• InChiKey: DZGKAEVQWRWBDF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  8-氨基-6-甲氧基喹啉 、 diallyl-(2-chloro-ethyl)-amine 在 乙醇 作用下， 生成 N,N-diallyl-N'-(6-methoxy-[8]quinolyl)-ethylenediamine
  参考文献：
  名称：

  Lu et al., Huaxue Xuebao/Acta Chimica Sinica, 1956, vol. 22, p. 589

  摘要：

  DOI：
• 作为产物：
  描述：

  N,N-二烯丙基乙醇胺 在 氯化亚砜 、 苯 作用下， 生成 diallyl-(2-chloro-ethyl)-amine
  参考文献：
  名称：

  Histamine Antagonists. VII. Phenothiazine Derivatives¹

  摘要：

  DOI：

  10.1021/ja01164a060

文献信息

• Urotensin-II receptor antagonists
  申请人：——

  公开号：US20030100580A1

  公开（公告）日：2003-05-29

  P51084 The present invention relates to sulfonamides, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.

  P51084这项发明涉及磺胺类化合物，含有它们的药物组合物，以及它们作为尿苷Ⅱ拮抗剂的用途。
• NOVEL INDOLIC DERIVATIVES, THEIR PREPARATION PROCESSES AND THEIR USES IN PARTICULAR AS ANTIBACTERIALS
  申请人：Denis Jean-Noel Marie Leon

  公开号：US20100144726A1

  公开（公告）日：2010-06-10

  The invention relates to the use of at least one compound of the formula (I), in which R and R 3 are particularly a hydrogen atom, R 1 is particularly a hydrogen atom or a methyl, ethyl or isobutyl mi group, R 4 , R 5 , R 6 and R 7 are independently a hydrogen atony, an alkoxyl group with 1 to 7 carbon atoms or a halogen atom, R 2 is a hydrogen atom, an O − group or an OH group, B is an N-GP 1 or NR c , group, GP 1 being a Boc or Cbz group, and R c is a hydrogen atom or a methyl or t-butyl group, for preparing a drug for treating conditions associated with bacterial infections, in particular for treating bacterial diseases.

  该发明涉及使用至少一种具有以下式（I）的化合物，其中R和R3特别是氢原子，R1特别是氢原子或甲基、乙基或异丁基mi基团，R4、R5、R6和R7独立地是氢原子、具有1至7个碳原子的烷氧基团或卤原子，R2是氢原子、O−基团或OH基团，B是N-GP1或NRc基团，GP1是Boc或Cbz基团，Rc是氢原子或甲基或叔丁基基团，用于制备用于治疗与细菌感染相关的疾病症状的药物，特别是用于治疗细菌性疾病。
• 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents
  申请人：——

  公开号：US20030181474A1

  公开（公告）日：2003-09-25

  Pyrimidine derivatives of formula (I) wherein Q 1 , Q 2 , G and R 1 are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described. 1

  该式中的嘧啶衍生物（I），其中Q1、Q2、G和R1如定义；以及其药用盐和体内可水解酯已被描述。还描述了它们的制造过程、药用组合物以及作为细胞周期依赖性丝氨酸/苏氨酸激酶（CDK）和焦点粘附激酶（FAK）抑制剂的用途。
• 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
  申请人：Merck Sante

  公开号：EP1801098A1

  公开（公告）日：2007-06-27

  The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.

  本发明涉及公式I的2-金刚烷基脲衍生物，作为选择性抑制酶11-β-羟基类固醇脱氢酶1（11β-HSD1）的药物，并利用这些化合物治疗和预防代谢综合征、糖尿病、胰岛素抵抗、肥胖、脂质紊乱、青光眼、骨质疏松症、认知障碍、焦虑、抑郁、免疫紊乱、高血压以及其他疾病和症状。
• 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents
  申请人：Pease Janet Elizabeth

  公开号：US20050090515A1

  公开（公告）日：2005-04-28

  Pyrimidine derivatives of formula (I) wherein Q 1 , Q 2 , G and R 1 are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.

  本文描述了式(I)的嘧啶衍生物，其中Q1、Q2、G和R1如定义所述；以及其药学上可接受的盐和体内可水解的酯。还描述了它们的制造过程、制药组合物以及它们作为细胞周期依赖性丝氨酸/苏氨酸激酶(CDK)和焦点粘附激酶(FAK)抑制剂的用途。